Witnessing the stock’s movement on the chart, on Wednesday, Inhibikase Therapeutics Inc (NASDAQ: IKT) had a quiet start as it plunged -5.50% to $1.89, before settling in for the price of $2.0 at the close. Taking a more long-term approach, IKT posted a 52-week range of $1.33-$3.35.
The Healthcare sector firm’s twelve-monthly sales growth has been 18.99% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 18.99%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 55.60%. This publicly-traded company’s shares outstanding now amounts to $121.27 million, simultaneously with a float of $99.08 million. The organization now has a market capitalization sitting at $229.19 million. At the time of writing, stock’s 50-day Moving Average stood at $1.62, while the 200-day Moving Average is $1.78.
Inhibikase Therapeutics Inc (IKT) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Inhibikase Therapeutics Inc’s current insider ownership accounts for 18.30%, in contrast to 41.38% institutional ownership. According to the most recent insider trade that took place on Nov 21 ’25, this organization’s 10% Owner bought 2,068,965 shares at the rate of 1.45, making the entire transaction reach 2,999,999 in total value, affecting insider ownership by 13,018,965.
Inhibikase Therapeutics Inc (IKT) Earnings and Revenue Records
Inhibikase Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 55.60% and is forecasted to reach -0.56 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 21.74% through the next 5 years, which can be compared against the 18.99% growth it accomplished over the previous five years trading on the market.
Inhibikase Therapeutics Inc (NASDAQ: IKT) Trading Performance Indicators
Let’s observe the current performance indicators for Inhibikase Therapeutics Inc (IKT). It’s Quick Ratio in the last reported quarter now stands at 11.67.
In the same vein, IKT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.57, a figure that is expected to reach -0.12 in the next quarter, and analysts are predicting that it will be -0.56 at the market close of one year from today.
Technical Analysis of Inhibikase Therapeutics Inc (IKT)
Going through the that latest performance of [Inhibikase Therapeutics Inc, IKT]. Its last 5-days volume of 0.62 million was inferior to the volume of 0.64 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 67.36% While, its Average True Range was 55.88.
Raw Stochastic average of Inhibikase Therapeutics Inc (IKT) in the period of the previous 100 days is set at 67.54%, which indicates a major rise in contrast to 55.82% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.17 that was higher than 0.12 volatility it exhibited in the past 100-days period.
